GMAB News
Genmab A/S
$56.70
-$0.59(-1.04%)
--
Overall
--
Value
--
Tech
--
Quality
Market Cap
--
Volume
3.86M
52W Range
$23.62 - $40.17
Target Price
--
GMAB news: the latest Genmab A/S headlines, press releases and market updates, newest first.
Latest GMAB News
- Analysts Conflicted on These Healthcare Names: Viking Therapeutics (VKTX) and Genmab (GMAB)TipRanks Newsroom · Oct 29, 2026
- Barclays Keeps Their Buy Rating on Genmab A/S (0MGB)TipRanks Auto-Generated Intelligence Newsdesk · Oct 29, 2026
- Goldman Sachs Sticks to Their Buy Rating for Genmab A/S (0MGB)TipRanks Auto-Generated Intelligence Newsdesk · Oct 29, 2026
- Analysts’ Top Healthcare Picks: Citius Oncology (CTOR), Genmab (GMAB)TipRanks Newsroom · Oct 28, 2026
- Genmab Stock (GMAB) Soars Over 30% on Strong Phase 3 Results for the Company’s Head and Neck Cancer TreatmentWilliam White · Oct 28, 2026
- Genmab’s Petosemtamab Combo Halves Risk of Death in Phase 3 Head and Neck Cancer TrialTipRanks Auto-Generated Newsdesk · Oct 28, 2026
- Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Genmab (GMAB) and Summit Therapeutics (SMMT)TipRanks Newsroom · Oct 28, 2026
- Genmab A/S (0MGB) Gets a Buy from BarclaysTipRanks Auto-Generated Intelligence Newsdesk · Oct 26, 2026
- Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Summit Therapeutics (SMMT) and Genmab (GMAB)TipRanks Newsroom · Oct 23, 2026
- Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Summit Therapeutics (SMMT) and Genmab (GMAB)TipRanks Newsroom · Oct 23, 2026
- Genmab’s Rina-S Delivers Breakthrough Phase 3 Results in Platinum-Resistant Ovarian CancerTipRanks Auto-Generated Newsdesk · Oct 23, 2026
- Genmab A/S (0MGB) Receives a Buy from BarclaysTipRanks Auto-Generated Intelligence Newsdesk · Oct 20, 2026
- Genmab (GMAB) Receives a Buy from Truist FinancialTipRanks Auto-Generated Intelligence Newsdesk · Oct 9, 2026
- Genmab Grants Restricted Stock Units to Board After Extraordinary General MeetingTipRanks Auto-Generated Newsdesk · Oct 7, 2026
- TD Cowen Sticks to Their Buy Rating for Genmab (GMAB)TipRanks Auto-Generated Intelligence Newsdesk · Oct 5, 2026
- Genmab and AbbVie Report Landmark Phase 3 Win for Epcoritamab Combo in Frontline DLBCLTipRanks Auto-Generated Newsdesk · Oct 5, 2026
- Genmab A/S (0MGB) Receives a Buy from JefferiesTipRanks Auto-Generated Intelligence Newsdesk · Oct 5, 2026
- Analysts Conflicted on These Healthcare Names: Pfizer (PFE) and Genmab (GMAB)TipRanks Newsroom · Oct 5, 2026
- Genmab Discloses Darwin Global as 5.11% Major ShareholderTipRanks Auto-Generated Newsdesk · Oct 2, 2026
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GMAB | $56.70 | -1.0% | 3.86M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |